By analyzing existing basic indicators between Biondvax Pharma and Arca Biopharma, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Arca Biopharma with a short position in Biondvax Pharma. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Biondvax is to check how much profit was generated for every dollar of assets it reports. Biondvax Pharma ADR shows a negative utilization of assets of -28.87 percent, losing $0.29 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Biondvax Pharma ADR shows how discouraging it operates for each dollar spent on its assets.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in BiondVax Pharmaceuticals. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its
performance over time. Several factors influence the investment perspective on BiondVax Pharmaceuticals, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
Watch out for price decline
Please consider monitoring BiondVax Pharmaceuticals on a daily basis if you are holding a position in it. BiondVax Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as BiondVax Pharmaceuticals stock to be traded above the $1 level to remain listed. If BiondVax Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is BiondVax Pharmaceuticals's Liquidity
BiondVax Pharmaceuticals
financial leverage refers to using borrowed capital as a funding source to finance BiondVax Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. BiondVax Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to BiondVax Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of BiondVax Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between BiondVax Pharmaceuticals's total debt and its cash.
Details
Cash and Equivalents Breakdown
Now, let's check Biondvax Pharma cash and equivalents. In accordance with the recently published financial statements, Biondvax Pharma ADR has 14.55
M in Cash and Equivalents. This is 98.23% lower than that of the Healthcare sector and 96.75% lower than that of the
Biotechnology industry. The cash and equivalents for all United States stocks is 99.46% higher than that of the firm. As for Arca Biopharma we see cash and equivalents of 63.2
M, which is 85.87% lower than that of the Biotechnology
| BVXV | 14.55 Million | 2.77 |
| Sector | 447.12 Million | 85.19 |
| ABIO | 63.2 Million | 12.04 |
Our perspective of the latest Biondvax Pharma climb
Latest jensen alpha indicator falls down to -0.64. Possible price increase?
As of the 22nd of December, Biondvax Pharma shows the
risk adjusted performance of
(0.12), and Mean Deviation of 2.95. Biondvax Pharma ADR
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen
technical drivers for Biondvax Pharma ADR, which can be compared to its rivals. Please confirm
Biondvax Pharma ADR coefficient of variation,
maximum drawdown, as well as the
relationship between the Maximum Drawdown and
skewness to decide if Biondvax Pharma ADR is priced correctly, providing market reflects its regular price of 2.92 per share. Please also double-check Biondvax Pharma ADR
total risk alpha, which is currently at
(0.83) to validate the company can sustain itself at a future point.
Our Final Takeaway
While some firms under the biotechnology industry are still a bit expensive, Biondvax Pharma may offer a potential longer-term growth to sophisticated investors. To sum up, as of the 22nd of December 2021, we believe Biondvax Pharma is currently
undervalued. It responds to the market and projects
very high chance of financial distress in the next two years. Our current 90 days buy-hold-sell recommendation on the venture is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of BiondVax Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
